Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication.

Sarcopenia refers to age-related muscle wasting, and has only been classified as a disease by the CDC since 2016. Drug developers have started to trickle into the space over the last five years, but there’s growing evidence that their initial focus on muscle mass is too simplistic...